Why compare them?
Both are represented in Weight management research, making their overlapping mechanisms and evidence maturity useful to compare.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
CagriSema vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceDirect comparison available
REIMAGINE 2 compared CagriSema 2.4 mg/2.4 mg with cagrilintide 2.4 mg, semaglutide 2.4 mg, lower-dose arms, and placebo for 68 weeks in adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor. It does not establish universal superiority for every population, goal, outcome, or dose.
✓ Shared
Shared Similarities
- Both records include AMY1R, AMY3R, and CTR.
- Both have been studied in Weight management.
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
CagriSema is distinguished by a fixed-dose combination: cagrilintide adds amylin-related signaling while semaglutide adds GLP-1 receptor agonism. Its outcomes belong to the combination, not either component alone; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
The biggest remaining question is how far the direct findings extend beyond the study's specific population, doses, endpoints, and duration.
Key Takeaways
CagriSema is distinguished in the current record by a fixed-dose combination: cagrilintide adds amylin-related signaling while semaglutide adds GLP-1 receptor agonism. Its outcomes belong to the combination, not either component alone. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagriSema
CagriSema: Strong Phase 3 evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
CagriSema: Investigational — U.S. application under review. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthCagriSema
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonAvailable
A direct study answers a defined question in a specific population, at specific doses, and over a specific duration.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
CagriSema
- Weight management
- Type 2 diabetes
- Glycemic control
- Add-on therapy to basal insulin
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
What it containsEvidence, not a winner
CagriSemaTwo components
Cagrilintide plus the GLP-1 receptor agonist semaglutide.
CagrilintideOne molecule
Long-acting amylin analogue with amylin- and calcitonin-receptor activity.
Direct 68-week weight comparisonEvidence, not a winner
CagriSema−14.2%
CagriSema 2.4 mg/2.4 mg arm in the same trial and estimand.
Cagrilintide−8.4%
Cagrilintide 2.4 mg arm in REIMAGINE 2 under the efficacy estimand.
Direct HbA1c comparisonEvidence, not a winner
CagriSema−1.91 points
CagriSema 2.4 mg/2.4 mg arm in the same trial.
Cagrilintide−0.80 points
Cagrilintide 2.4 mg arm in the type 2 diabetes trial.
Weight evidence without diabetesEvidence, not a winner
CagriSema3,417-person Phase 3
REDEFINE 1 reported −20.4% versus −3.0% placebo under the treatment-policy estimand.
CagrilintidePhase 2 + component arm
Standalone evidence is smaller, with dedicated RENEW Phase 3 results pending.
Regulatory positionEvidence, not a winner
CagriSemaApplication under review
U.S. submission made in December 2025; no approval identified by the cutoff.
CagrilintideInvestigational
Standalone Phase 3 program active; no FDA-approved product.
Using both togetherEvidence, not a winner
CagriSemaDirect overlap
No compatibility or benefit should be inferred from duplicating the component.
CagrilintideDuplicate ingredient
CagriSema already includes cagrilintide.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Direct comparison available
- The direct comparison applies only to its defined population, doses, endpoints, and duration.
- It does not answer every regulatory, long-term, formulation, route, or individual-use question.
- A direct result should not be generalized into an objectively “better” compound.
Pathway boundary: CagriSema already contains cagrilintide. Adding standalone cagrilintide would duplicate an active ingredient and its amylin/calcitonin-related receptor activity; this is clear ingredient overlap, not an unstudied complementary stack.
Current unknowns
Questions the evidence cannot answer yet
- The FDA decision and final label, long-term cardiovascular and renal outcomes, rare events, and durability after discontinuation.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
CagriSema
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.